



May 13, 2026

**BSE Limited**

The Listing Department  
Phiroze Jeejeebhoy Towers  
25<sup>th</sup> Floor, Dalal Street  
Fort, Mumbai 400 001  
Maharashtra, India

BSE Scrip Code: 544309

**National Stock Exchange of India Limited**

The Listing Department  
Exchange Plaza, Plot No. C/1, G Block,  
Bandra Kurla Complex  
Bandra (East), Mumbai 400051  
Maharashtra, India

NSE Symbol: IKS

Dear Sir/Ma'am,

**Sub: Investor Presentation**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith investor presentation on the financial results of the Company for the quarter and year ended March 31, 2026.

The said presentation are also being uploaded on the website of the Company at the <https://ikshealth.com/investor-relations/>

Request you to take it on record and disseminate the same on your website.

Thanking you.

Yours sincerely,  
**For Inventurus Knowledge Solutions Limited**

**Sameer Chavan**  
**Company Secretary and Compliance Officer**  
Membership No. F7211

Encl: As above


# IKS Health

Q4 FY 26 Investor Presentation

# Disclaimer

This presentation may include opinions and assumptions about future performance which could be considered as forward-looking statements. Forward-looking statements intrinsically cover several risks and uncertainties, which may lead to a material difference between actual results and the statements themselves. Such statements comprise the company's current visibility on market movements, client discussions, and related factors. Inventurus Knowledge Solutions Limited does not assume an obligation to update or revise any forward-looking statements.

# IKS Health – a comprehensive healthcare enablement platform empowering provider organizations



# IKS Health: 5 Strategic Pillars of execution



**AI-native. Agentic Platform Manifest**

- Launched interconnected agentic workflow for autonomous Clinical Documentation, Coding and Prior Authorization
- Launched Scribble Now; launching multi-variant scribble
- Developed Autonomous Coding for two medical specialities, optimizing and expanding to other specialties
- MyCarehub - Multi agent orchestration across patient engagement features.

**AQuity Acquisition Integration & Optimization**

- Integration ✓✓✓
- Margin expansion ✓✓
- Cross Sell motion ✓

**Establishing Leadership across features; while driving platform uniqueness**

- #1 in AI-driven RCM and Medical coding by Blackbook
- # 1 in Clinical documentation by Blackbook and KLAS
- Top performer in ambulatory RCM by KLAS

**Differentiated Growth Market Strategy**

- Secured marquee platform wins in Independent Groups and Small/Medium Health Systems
- Point solution Land and Expand in large Health Systems

**Evolution Towards an Outcome-Oriented Company**

- Cultivating outcome-oriented deals that drive stickiness and additional economic pools
- Building capability to drive outcomes
- \$3 million NEVA earned in Palomar in first year despite staggered implementation

# Awards and Recognition



**ET Edge Best Organisations for Women 2026**



**Financial Express AICONIC Award 2026**  
**Best Use of AI in Healthcare & Lifesciences**

**IKS Health Virtual Care Assistant**


# Accelerating AI Initiatives



Partnership with Certilytics, an innovator in AI driven healthcare intelligence, to connect payer rules and provider workflows using agentic AI, human oversight, and unified action



Strategic acquire of ThinkDTM, an AI-native product, strategy, and digital services company, including ThinkDTM Founder Tij Bedi and team of AI experts on patient access solutions portfolio.




Launched AI-driven revenue cycle management (RCM), audit-ready, autonomous coding engine delivering up to 95% coding accuracy while reducing denials. The solution is integrated with Epic (available in Epic Connection Hub) and combines AI-driven code assignment with expert human review to deliver accurate, audit-ready codes from chart to claim.



Launched MyCareHub™, an agentic AI self-orchestrating platform that uses an active, aware and constant multi-agent behavioral algorithm to create an adaptive and autonomous patient engagement operating system, integrated with Epic (available in Epic Connection Hub)

# IKS Health enables care transformation across the patient journey




### Legend


**Automation Level**

1	2	3	4	5
Fully Manual			Fully Autonomous	

# Q4 – Strong growth while delivering *continuous margin expansion*



# Key Deal Wins



IKS Health has entered a strategic multi-year full platform partnership with Holyoke Medical Center, a legacy Aquity customer. This collaboration leverages AI-driven and human-led solutions to reduce administrative burden, lower costs, and drive new revenue for the hospital's financial stability and sustainable growth.



IKS Health has expanded the platform relationship to include development of advanced AI capabilities within the hospital environment to improve operational efficiencies.




**Top 5 Health System**


Expanded the existing Revenue Cycle Management (RCM) and Value-Based Care (VBC) partnership with a top 5 health system to encompass additional regions and states within the scope of IKS Services.

# Q4 FY 26: Growing *faster than market* with *improving margins*


**Revenue**  
INR Mn




**EBITDA**  
INR Mn



**PAT\***  
INR Mn



**Adjusted PAT\*\***  
INR Mn




\*PAT includes a ₹127 million non-recurring, non-cash write-off of unamortized debt cost, resulting from loan refinancing at favourable terms.

\*\*Adjusted PAT is adjusted for amortization of intangible assets recognised on acquisition and write off of unamortized debt cost due to refinancing of existing loan on favourable terms both of which are non-cash expenses.


# Q4 FY 26 – Improving EPS and maintaining high ROE

## EPS ₹




EPS is calculated as profit for the period divided by weighted average number of equity shares as defined in IND AS 33.

## ROE %




Return on Equity is calculated as profit for the period divided by average equity balance during the period.

# FY 26 – Strong growth while delivering *continuous margin expansion*




# FY 26: Growing *faster than market* with *improving margins*

**Revenue**  
INR Mn




↑ 19.9% YoY

**EBITDA**  
INR Mn




↑ 38.0% YoY

**PAT\***  
INR Mn



↑ 48.4% YoY

**Adjusted PAT\*\***  
INR Mn




↑ 46.9% YoY


\*PAT includes a ₹127 million non-recurring, non-cash write-off of unamortized debt cost, resulting from loan refinancing at favourable terms.

\*\*Adjusted PAT is adjusted for amortization of intangible assets recognised on acquisition and write off of unamortized debt cost due to refinancing of existing loan on favourable terms both of which are non-cash expenses.

# FY 26 – Improving EPS and maintaining high ROE



EPS is calculated as profit for the period divided by weighted average number of equity shares as defined in IND AS 33.




Return on Equity is calculated as profit for the period divided by average equity balance during the period.




\*EPS and ROE includes a ₹127 million non-recurring, non-cash write-off of unamortized debt cost, resulting from loan refinancing at favourable terms.

# FY 26 – *Strong Cash Generation* supporting growth aspirations

## OCF & FCF INR Mn



## Net Debt INR Mn




# A Decade of *Consistent Profitable Growth*

INR Mn

■ Revenue ■ PAT

**28.7%**  
**Revenue CAGR**

**46.4%**  
**PAT CAGR**



# Financials - Summary INR millions

Particulars	Q4 FY 26	Q3 FY 26	QoQ%	Q4 FY 25	YoY%	FY 26	FY 25	YoY%
Revenue USD mn	95	93	2.4%	84	12.6%	364	316	15.4%
Revenue	8,577	8,150	5.2%	7,240	18.5%	31,938	26,640	19.9%
Other Income - Operating	-	-	0.0%		0.0%		176	-100.0%
Forex Gain/ (Loss)	352	87	303.3%	(24)	-1587.4%	627	38	1552.5%
Employee benefit expense excluding ESOP	4,011	3,947	1.6%	3,749	7.0%	15,803	14,669	7.7%
Other Expenses	1,743	1,362	28.0%	1,089	60.1%	5,379	3,997	34.6%
<b>Adjusted EBITDA</b>	<b>3,175</b>	<b>2,928</b>	<b>8.4%</b>	<b>2,378</b>	<b>33.5%</b>	<b>11,383</b>	<b>8,188</b>	<b>39.0%</b>
<b>Adjusted EBITDA %</b>	<b>37.0%</b>	<b>35.9%</b>	<b>1.1%</b>	<b>32.8%</b>	<b>4.2%</b>	<b>35.6%</b>	<b>30.7%</b>	<b>4.9%</b>
ESOP Cost	173	112	53.4%	116	48.5%	470	277	69.4%
<b>EBITDA</b>	<b>3,002</b>	<b>2,816</b>	<b>6.6%</b>	<b>2,262</b>	<b>32.7%</b>	<b>10,913</b>	<b>7,911</b>	<b>38.0%</b>
<b>EBITDA %</b>	<b>35.0%</b>	<b>34.6%</b>	<b>0.5%</b>	<b>31.2%</b>	<b>3.8%</b>	<b>34.2%</b>	<b>29.7%</b>	<b>4.5%</b>
Finance cost*	127	233	-45.7%	210	-39.7%	702	898	-21.7%
Depreciation and amortisation	341	320	6.3%	283	20.2%	1,242	1,127	10.2%
Interest income	49	56	-12.2%	33	49.4%	172	176	-2.5%
<b>Profit before exceptional items and tax</b>	<b>2,584</b>	<b>2,318</b>	<b>11.5%</b>	<b>1,801</b>	<b>43.5%</b>	<b>9,141</b>	<b>6,063</b>	<b>50.8%</b>
<b>Profit before exceptional items and tax %</b>	<b>30.1%</b>	<b>28.4%</b>	<b>1.7%</b>	<b>24.9%</b>	<b>5.2%</b>	<b>28.6%</b>	<b>22.8%</b>	<b>5.9%</b>
Tax expense	470	460	2.1%	323	45.5%	1,834	1,202	52.5%
<b>Profit for the period before Share of Associates</b>	<b>2,114</b>	<b>1,857</b>	<b>13.8%</b>	<b>1,478</b>	<b>43.0%</b>	<b>7,308</b>	<b>4,861</b>	<b>50.3%</b>
<b>Profit for the period before Share of Associates %</b>	<b>24.6%</b>	<b>22.8%</b>	<b>1.9%</b>	<b>20.4%</b>	<b>4.2%</b>	<b>22.9%</b>	<b>18.2%</b>	<b>4.6%</b>
Share of Profit/(Loss) from Associates (net of tax)	(54)	(24)	125.7%		0.0%	(92)		0.0%
<b>Profit for the period</b>	<b>2,060</b>	<b>1,833</b>	<b>12.3%</b>	<b>1,478</b>	<b>39.4%</b>	<b>7,216</b>	<b>4,861</b>	<b>48.4%</b>
<b>Profit for the period %</b>	<b>24.0%</b>	<b>22.5%</b>	<b>1.5%</b>	<b>20.4%</b>	<b>3.6%</b>	<b>22.6%</b>	<b>18.2%</b>	<b>4.3%</b>
Unamortised Debt Cost written off*		127	-100.0%	-	0.0%	127	-	0.0%
Amortisation of Intangible assets	210	194	8.3%	168	24.8%	744	643	15.8%
<b>Adjusted Profit for the period</b>	<b>2,269</b>	<b>2,154</b>	<b>5.4%</b>	<b>1,646</b>	<b>37.9%</b>	<b>8,087</b>	<b>5,504</b>	<b>46.9%</b>
<b>Adjusted Profit for the period %</b>	<b>26.5%</b>	<b>26.4%</b>	<b>0.0%</b>	<b>22.7%</b>	<b>3.7%</b>	<b>25.3%</b>	<b>20.7%</b>	<b>4.7%</b>

# Other KPI Metrics


Particulars	FY 26	FY 25
Adjusted EBITDA per employee	0.88	0.63
Revenue from Top 10 customers INR mn	11,811	9,230
Contribution from Top 10 customers	37.0%	34.6%
Revenue from Top 5 customers INR mn	6,856	5,828
Contribution from Top 5 customers	21.5%	21.9%
Ageing of Top 10 clients (number of years)	5.94	6.20
Ageing of Top 5 clients (number of years)	5.82	8.57
FCF Yield	84.9%	56.7%
Clients with revenue >\$1mn	66	69

Strategic Growth


---

# Proposed Acquisition of TruBridge

# System of Action + System of Record → Operating System for Healthcare



# Strategic Acquisition: TruBridge



## IKS Health Vision FY 2030

₹ Crores	LTM December 2025	FY 30
<b>EBITDA</b>	₹ 1000	₹ 3000
<b>Net Debt</b>	₹ 300	Similar to Dec 2025

Technology advancement

---

# Proposed Acquisition of ARAI

# ARAI – Founding team



## Dr. Asoke Talukder

Co-Founder & CAIO  
Adj Faculty, CSE, NITK Surathkal

Dr Asoke Kumar Talukder is a serial entrepreneur and polymath. He is a Physicist by training, Data Scientist by choice, and Biomedical Scientist by passion.

He has contributed significantly to the field of Artificial Intelligence, Data Sciences, Omic sciences, Systems Biology, Knowledge engineering, Mobile computing and Information Security

He has worked in India, USA, UK, and Singapore in the domains of Product Innovation for companies like ICL, Fujitsu-ICIM, Microsoft, Oracle, Informix, Digital, Hewlett Packard, Sequoia, Northern Telecom, NEC, KredietBank, iGate, Cellnext, Tyfone etc.

He is the author / editor six books and has published 80+ peer reviewed research papers.



## Dr. Roland Haas

Co-Founder & CEO  
Professor at IITB

Born and raised in Germany, Dr. Haas studied Computer Science, Mathematics, and Electrical Engineering and has more than 30 years of experience across techno - managerial, research, and BD positions in Europe, USA, and Asia.

He is also an expert reviewer for cybersecurity of critical infra.

His teaching and research interests cover AI/ML, Gen AI, Deep Learning, Cyber-Physical Systems, Cybersecurity, Autonomous Systems,, Healthcare AI and Clinical Decision Support Systems. He is the author of four books and has published 80+ peer reviewed research papers

# IKS Health AI Strategy and the Gap

IKS is executing a strong AI roadmap — with ARAI, we will rely much lesser on third party models

## What IKS Already Has

- Agentic AI platform built on Google Cloud / Gemini
- Scribble Suite — ambient AI scribe (Epic-integrated, KLAS #1 2026)
- AI-driven RCM coding: 89% automation, 88%+ accuracy
- Human-in-the-loop model for compliance & accuracy
- Investments in other AI accelerators
- 2025 Google Cloud DORA Award for AI augmentation
- Black Book #1: AI-driven RCM, clinical documentation (12 years)

## The Gap — What ARAI Brings

- Accelerates IKS's AI R&D with expertise to build models for RCM (denials prediction)
- AI models that enable humans to understand, trust & interpret the output - thereby building trust through transparency
- Knowledge graph IP for clinical reasoning
- Clinical Decision Support Systems (CDSS)
- Secure and Robust AI with reduced hallucination
- Scalable R&D talent pipeline and mentorship

# Buy Vs Build – Accelerating Time to Market

## Acquisition Price

\$1.2M in upfront cash for acquiring the IP

Discounted ESOPs over 4 years to align long term interest

## Build Vs. Buy – Cost Avoidance Analysis

**\$8–12M**



Estimated Build Cost (Internal Engineering)

**2–3 Yrs**



Time-to-Parity if all the Knowledge Graphs are Built Internally

**30% Increase in efficiency**



Reduction in number of tokens to achieve the same objective

## ARAI's IP slot directly into three revenue-generating AI workstreams already under development

**Autonomous Medical Coding**

**\$15–25M**

Addressable Annual Revenue

**Denials Prediction & Prevention**

**30–40%**

Reduction in Denial Rates

**Clinical Decision Support Products**

**12–18 Mo**

Faster Time to Market

# Joint Value Proposition: IKS + ARAI + TruBridge

## One Integrated System – Compounding Value creation

**SYSTEM OF RECORD  
(Stores the record)**

**TruBridge EHR**  
Via EHR + Services

**WHAT IT DOES**

---

The trusted clinical record market leader for rural and community hospitals – patient history, orders, medications, diagnoses.

- Live clinical data
- Leading EHR vendor for rural and community hospitals
- Being upgraded to modern tech stack in 18 months

**INTELLIGENCE LAYER  
(Makes it smart)**

**ARAI Solutions**  
AI Brain

**WHAT IT DOES**

---

Peer-reviewed clinical AI that understands medical relationships and validates every decision before it acts.

- Proprietary Knowledge Graphs provide intelligent reasoning layer that checks AI outputs against medical knowledge
- ARAI's Clinical Ontology layer differentiates IKS as a full-stack company with proprietary domain intelligence

**SYSTEM OF ACTION  
(Makes it actionable)**

**IKS Health**  
Care Enablement Platform

**WHAT IT DOES**

---

The operating layer that takes clinical data and turns it into completed tasks – billing, prior authorizations, documentation, coding.

- 600+ clients across multiple service lines, 24% revenue growth
- Handles the full care journey – both acute and ambulatory
- Agentic AI with a Human in the Loop model

### WHAT THIS CREATES TOGETHER

**For Hospitals**

One system that holds their patient records and handles their admin – billing, coding, prior auth – automatically, with no extra software vendors to manage.

**For Physicians**

AI that documents visits, surfaces missed diagnoses, and checks prescriptions in real time – giving time back to patient care without changing clinical workflows.

**For IKS Shareholders**


A defensible platform business: 2,000+ healthcare organizations, owned AI IP, and revenue expansion opportunities as customers gravitate towards an integrated System of Action & Record provider



**IKS CARES**  
FOUNDATION


# 2025-26: A Story of Expansion

- With a focus on constantly improving access to quality primary healthcare for underprivileged communities, IKS Cares Foundation has been expanding its scope of work – to cover a **wider range of health needs**, beneficiaries, and **geographies**.
- Newly added in 2025-26: Dental Health Camps & Expansion into Telangana



**Anemia in  
Women &  
Children**

+



**Diabetes in  
Adults**

+




**Dental Care for All  
Ages (Onsite)**

**Maharashtra**




+

**Telangana**



# More than doubling the impact in FY2025-26

- **From 15,118** screenings in it's first year and a half of existence, IKS Cares has screened **over 30,000** children and adults in FY25-26 **alone**
- In addition, live, on-site dental treatment addresses a huge unmet need



# Key Programs: Mumbai and Hyderabad



**Free Mobile Clinics for Anemia and Diabetes** – Mobile clinics, led by IKS’s medical personnel, offer the latest diagnostic facilities, physical examination by our doctors, free medication, and follow up checks.

**Free Mobile Dental Health** – IKS’s dentists deliver live, on-site treatment in the form of ultra-sound scaling, filling of primary cavities, fluoride based preventive care, and free medication for pain and infections.



**Diagnostic Support Services** – To conduct basic haematological investigations to diagnose Anemia and Diabetes; To screen children for oral health and provide dental care treatment on-site – a vast unmet need across India.



**Patient Education** – To raise awareness about preventive healthcare issues and the importance of dental hygiene  
**Integration** – To integrate patients into existing programs



**Curative Healthcare** – To prescribe and dispense medicines for common ailments



**Follow-up Care** – To ensure that the prescribed medication doses are being provided and taken according to the schedule. To check for improvement in status post-medication.

# Medical Camps: Impact as of end March 2026

**194**

**MEDICAL CAMPS**

of which 112 were in  
FY25-26

**45577**

**SCREENED**

As of March, 2026.

**15931**

**DIAGNOSED AS ANEMIC**

**110+**

**FOLLOW-UP  
CAMPS**



**Follow Up &  
Medications  
Provided**

**73%**

**Children  
Positively Impacted**

**42%**

**Children  
Moved From Anemic  
To Non-Anemic Level**

# Dental Camps: Impact as of end March 2026

15

DENTAL CAMPS

1789

DENTAL SCREENINGS

915

DENTAL TREATMENTS

As of March, 2026.

- Complete oral health assessment
- Ultrasonic scaling (Cleaning of teeth)
- Filling primary cavities: GIC & Composite Restorations
- Fluoride based preventive treatments
- Medications for pain, infection management



**IKS CARES**  
FOUNDATION

**Thank You**

